

# Thomas Mikeska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7811882/publications.pdf>

Version: 2024-02-01

47  
papers

3,068  
citations

257101

24  
h-index

243296

44  
g-index

47  
all docs

47  
docs citations

47  
times ranked

6371  
citing authors

#	ARTICLE	IF	CITATIONS
1	BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. <i>Bioinformatics</i> , 2005, 21, 4067-4068.	1.8	554
2	Silencing of <i>Irf7</i> pathways in breast cancer cells promotes bone metastasis through immune escape. <i>Nature Medicine</i> , 2012, 18, 1224-1231.	15.2	406
3	DNA Methylation Biomarkers: Cancer and Beyond. <i>Genes</i> , 2014, 5, 821-864.	1.0	236
4	Optimization of Quantitative MGMT Promoter Methylation Analysis Using Pyrosequencing and Combined Bisulfite Restriction Analysis. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 368-381.	1.2	194
5	CpG Island Methylation in Human Lymphocytes Is Highly Correlated with DNA Sequence, Repeats, and Predicted DNA Structure. <i>PLoS Genetics</i> , 2006, 2, e26.	1.5	183
6	Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. <i>Nucleic Acids Research</i> , 2008, 36, e42-e42.	6.5	159
7	DNA methylation biomarkers in cancer: progress towards clinical implementation. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 473-487.	1.5	146
8	The implications of heterogeneous DNA methylation for the accurate quantification of methylation. <i>Epigenomics</i> , 2010, 2, 561-573.	1.0	126
9	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	3.2	79
10	Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 3474-3484.	3.2	76
11	Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. <i>Cancer Research</i> , 2010, 70, 1689-1699.	0.4	66
12	Epigenetic silencing of the candidate tumor suppressor gene <i>PROX1</i> in sporadic breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 547-554.	2.3	65
13	Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the <i>CDKN2B</i> ( <i>p15</i> ) gene. <i>Epigenetics and Chromatin</i> , 2008, 1, 7.	1.8	65
14	Oncogenic <i>HRAS</i> suppresses clusterin expression through promoter hypermethylation. <i>Oncogene</i> , 2006, 25, 4890-4903.	2.6	61
15	Analysing DNA Methylation Using Bisulphite Pyrosequencing. <i>Methods in Molecular Biology</i> , 2011, 791, 33-53.	0.4	61
16	Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. <i>Epigenetics</i> , 2011, 6, 500-507.	1.3	61
17	Mutations of the Wnt antagonist <i>AXIN2</i> (Conductin) result in TCF-dependent transcription in medulloblastomas. <i>International Journal of Cancer</i> , 2007, 121, 284-291.	2.3	60
18	A systematic search for DNA methyltransferase polymorphisms reveals a rare <i>DNMT3L</i> variant associated with subtelomeric hypomethylation. <i>Human Molecular Genetics</i> , 2009, 18, 1755-1768.	1.4	55

#	ARTICLE	IF	CITATIONS
19	Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated Bâ€Raf. <i>International Journal of Cancer</i> , 2009, 125, 297-307.	2.3	36
20	Aberrant Methylation and Reduced Expression of LHX9 in Malignant Gliomas of Childhood. <i>Neoplasia</i> , 2009, 11, 700-711.	2.3	36
21	Fc-Î³ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2435-2444.	3.2	33
22	Validation of a primer optimisation matrix to improve the performance of reverse transcription â€“ quantitative real-time PCR assays. <i>BMC Research Notes</i> , 2009, 2, 112.	0.6	31
23	SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas. <i>Oncogene</i> , 2007, 26, 5662-5668.	2.6	25
24	MethMarker: user-friendly design and optimization of gene-specific DNA methylation assays. <i>Genome Biology</i> , 2009, 10, R105.	13.9	25
25	RANK (TNFRSF11A) Is Epigenetically Inactivated and Induces Apoptosis in Gliomas. <i>Neoplasia</i> , 2012, 14, 526-IN12.	2.3	25
26	Quality control of astrocyteâ€directed Cre transgenic mice: The benefits of a direct link between loss of gene expression and reporter activation. <i>Glia</i> , 2009, 57, 680-692.	2.5	22
27	p75 <sup>NTR</sup> induces apoptosis in medulloblastoma cells. <i>International Journal of Cancer</i> , 2011, 128, 1804-1812.	2.3	22
28	MethPat: a tool for the analysis and visualisation of complex methylation patterns obtained by massively parallel sequencing. <i>BMC Bioinformatics</i> , 2016, 17, 98.	1.2	22
29	In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. <i>British Journal of Cancer</i> , 2008, 99, 294-304.	2.9	17
30	A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues. <i>BMC Biotechnology</i> , 2010, 10, 89.	1.7	17
31	Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 319-329.	1.1	16
32	DNA methylation analysis of the HIFâ€1± prolyl hydroxylase domain genes <i>PHD1</i> , <i>PHD2</i> , <i>PHD3</i> and the factor inhibiting HIF gene <i>FIH</i> in invasive breast carcinomas. <i>Histopathology</i> , 2010, 57, 451-460.	1.6	15
33	Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. <i>BMC Cancer</i> , 2015, 15, 669.	1.1	14
34	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. <i>Oncotarget</i> , 2017, 8, 83626-83636.	0.8	13
35	Closed-Tube PCR Methods for Locus-Specific DNA Methylation Analysis. <i>Methods in Molecular Biology</i> , 2011, 791, 55-71.	0.4	12
36	Assessing alternative base substitutions at primer CpG sites to optimise unbiased PCR amplification of methylated sequences. <i>Clinical Epigenetics</i> , 2017, 9, 31.	1.8	10

#	ARTICLE	IF	CITATIONS
37	No evidence for PALB2 methylation in high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2013, 6, 26.	1.3	8
38	No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1420-1422.	0.6	4
39	Exemplary multiplex bisulfite amplicon data used to demonstrate the utility of Methpat. <i>GigaScience</i> , 2015, 4, 55.	3.3	3
40	Crystal structures of O-acetylated 2-acylamino-2-deoxy-d-galactose derivatives. <i>Carbohydrate Research</i> , 2003, 338, 2119-2128.	1.1	2
41	(4S,5S)-4-[(1R)-1,2-Dihydroxyethyl]-5-tridecyl-1,3-oxazolidin-2-one. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2003, 59, o225-o227.	0.4	2
42	1,1-Dimethylethyl-N-propanoylcarbamate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2003, 59, o1359-o1361.	0.2	2
43	tert-Butyl 4-acetyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylate. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2002, 58, o359-o361.	0.2	1
44	2(S)-N-tert-Butoxycarbonylamino-N-methoxy-N-methylbutanamide. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2002, 58, o1415-o1417.	0.2	1
45	Epigenetic Basis of Human Cancer. , 2017, , 83-102.		1
46	6(S)-Methyl-3(S)-(1-methylethyl)piperazin-2-one. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2003, 59, o171-o173.	0.2	0
47	1.31 Investigating Methylation of the Pro-Apoptotic CLL Tumour Suppressor Gene, Death Associated Protein Kinase 1 (DAPK1). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S159.	0.2	0